EU-ToxRisk Virtual Open Symposium

        23-24 February 2021

Welcome to the registration page of the EU-ToxRisk online Open Symposium 2021, taking place on Tue 23 + Wed 24 February 2021.

OBJECTIVES OF THE MEETING

• Critical assessment of general and specific learnings of the EU-ToxRisk project and its resulting key deliverable, the Advisory document on NAM-enhanced read-across, including feedback and endorsements from the Regulatory Advisory Board, the OECD IATA Case Studies Project, and international regulatory toxicologists, as well as outlining of remaining challenges (Session 1).
• Presentation of novel running case studies with new challenging regulatory and scientific questions, such as testing of chemicals with little or no observed adverse effects, with multi-target organ toxicity, which undergo metabolism, or with the need for ab-initio risk assessment (Sessions 2+3).
• Outlook towards future validation approaches and application of NAMs for risk assessment in new frameworks, projects, and partnerships, including a platform to jump-start new efforts in next-generation risk assessment (Sessions 4+5).

PROGRAMME

The programme of the Open Symposium is divided into a total of 5 public sessions, followed by 1 closed session, which is restricted to EU-ToxRisk members, RAB, SAB. The sessions will cover two afternoons: 

DAY-1, Tue 23 Feb 2021 (13:00 - 17:30pm CET)

• Session 1 (public): Release of the EU-ToxRisk Advisory Document on NAM-enhanced read-across
• Session 2 (public): Round-2 case studies – New challenges for NAM-based risk assessment

DAY-2, Wed 24 Feb 2021 (13:00 - 17:30pm CET)

• Session 3 (public): Next-generation risk assessment by new-generation scientists (speed talks)
• Session 4 (public): Validation strategies for NAMs
• Session 5 (public): EU-ToxRisk sustainability
• Closed session: Feedback from the EU-ToxRisk SAB + RAB to the consortium

Documents supporting the event programme (available for download in the "FILES" section further down):

• Detailed event agenda
• Booklet presenting the speed talks and their respective abstracts (Session 3/DAY-2)

For more information on the EU-ToxRisk project Case Studies, please visit the Case Study section on our public project website, here.

VIRTUAL MEETING ROOM

The Open Symposium is organised as an online event: 

• ZOOM - Main meeting room: 
  • The main meeting room, where all presentations and live discussions will take place, will be ZOOM.
  • While listening to the presentations, please make sure to mute your microphone and to turn off your camera, to save band-width.
  • To ask questions during the presentations, please use the "CHAT" function, to avoid interrupting the speakers. Your questions will then be picked up in the Q&A slot at the end of the concerned session.
  • The ZOOM connection details will be provided to the registered participants by e-mail.
• Slack channel:
  • In parallel to ZOOM, a Slack channel will be available for questions and discussions throughout the meeting.
  • Like ZOOM, Slack allows you to send in your questions for the Q&A slots of the different sessions.
  • In addition to the questions you might want to ask, Slack is also the perfect place to launch/participate in discussions on the various meeting topics.
  • The SLACK connection details will be provided to the registered participants by e-mail.
• Contact form for burning questions:
  • If you wish to send in any burning questions already ahead of the meeting, please use this form, where you can choose the recipient of your questions: (1) EU-ToxRisk consortium; (2) EU-ToxRisk Regulatory Advisory Board (RAB).
  • These questions will also be addressed in the Q&A slots, as appropriate.

REGISTRATION

>> Registration is closed; the max number of attendees has been reached. Thank you for your understanding. <<

QUESTIONS

If you have any questions regarding this event, or issues with registration, please contact the Project Office.

*   *   *   *   *   *

This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement N° 681002.